Grünenthal successfully completes Phase I trial with Nociceptin Receptor (NOP) Agonist

The investigational compound has a unique mechanism of action and the potential to become a first-in-class therapy option for the treatment of acute and chronic pain. In a Phase I trial, the investigational compound was demonstrated to be safe and well tolerated. A Phase II trial will...